UGC
Global Upper Gastrointestinal (GI) Series Market is estimated to reach around US$ XX Bn by 2027, growing at a CAGR of 5.4% during the forecasted period.Market Definition:An Upper Gastrointestinal (GI) is a Series of X-rays visualizing the esophagus, stomach, and small intestine after the patient swallow a chalky substance barium solution.Approximately 60-70 million people are by major and minor GI disease or disorder.The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.Global Upper Gastrointestinal (GI) Series Market: Market Dynamics:In the report, under the Market Dynamics Global Upper Gastrointestinal (GI) Series Market covers the exhaustive study and analysis on market size, growth, drivers, restraints, challenges and opportunities faced by the industry.Moreover, Growing geriatric population, and increasing government support for the R in the market have also affected the growth positively.Each year, more than 100 million people are diagnosed with a GI disorder, resulting in 200 million sick days, 50 million medical visits, 16.9 million days lost from school, 10 million hospitalizations and nearly 200,000 deaths per yearHowever, limited applications of the treatment availability of alternative therapies, the side effect of drugs, lack of awareness regarding treatment in rural areas are some of the factors likely to hamper the growth of the Global Upper Gastrointestinal (GI) Series Market.Hence, giving Opportunities for development of new, innovative and more cost-effective treatments.• Gastroenterology market is set to expand because of the growing population and increasing pharmaceutical companies that recognize the necessity and significance of developing innovative treatments and advancement of Research and development in Upper Gastrointestinal.• Gastrointestinal Clinical trials activities conducted by Agency, such as FDA, National Gastrointestinal Foundation, in developing newly diagnosed medicines for gastrointestinal disease.Global Upper Gastrointestinal (GI) Series Market: Market Segmentation:The report covers the comprehensive analytical segments of the Upper Gastrointestinal (GI) Series Market thereby providing a brief insight into the small and large sector.
UGC
The global human microbiome therapeutics market size is expected to reach USD 1,544.6 million by 2027 according to a new study by Polaris Market Research.The report “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, and Prescription Drugs); By Therapeutic Area (Autoimmune Disorders, Dental Disorders, Digestive and Gastrointestinal Disorders, Dermatological Disorders, Infectious Disease, Metabolic Disorders, Oncology, and Others); By Indication (Acne Vulgaris, Atopic Dermatitis, Clostridium difficile Infection, Colorectal Cancer, Diabetes, Inflammatory Bowel Disease (IBD), Lactose Intolerance, Lung Cancer, Non-alcoholic steatohepatitis (NASH), Obesity, and Coeliac Disease); By Approach (Small Molecule Therapies, Single Strain Whole Bacteria, Microbial Consortia, Genetically Modified Single Strain Bacteria, Phage Cocktail, and Microbial Ecosystems), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.Microbiome refers to the residing micro-organisms genomes in the human body, particularly in the gut.The human body comprises more than 100 trillion microbes and around 2 million microbe genomes.The majority of these are strict anaerobes, with fungi and archaebacteria comprising less than 1 per cent of the total population.Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/human-microbiome-therapeutics-market/request-for-sample The global market is driven by an increased focus on microbiome based early diagnosis of diseases, increase in the prevalence of diseases due to dysbiosis, rising collaborations, and strongly funded government backed microbiome research projects.
UGC
Duodenoscopes Market Information: By Types, (Rigid Duodenoscopes and Flexible Duodenoscopes), By Application, (Diagnosis and Treatment), By End User (Gastrologists, General and Pediatric Surgeons, Hospitals, Speciality Clinics, and Others) – Global Forecast till 2023Global Duodenoscopes Market – OverviewDuodenoscope is flexible, lighted weighted tubes that are released through the mouth, throat, and stomach into the top of the small intestine.Duodenoscopes are being used in more than 650,000 gastrointestinal procedures in the U.S every year.This is a minimally invasive way to drain out fluids from biliary and pancreatic ducts which are blocked by cancerous tumors, gallstones or others.In 2013, the Centers for Disease Control and Prevention (CDC) alerted the FDA regarding possible association of multidrug resistant bacterial infections and duodenoscopes.From January 2013 through December 2014, ERCP was associated with infections in 135 patients.FUJIFILM Holdings Corporation, KARL STORZ GmbH & Co. KG, PENTAX Medical, Olympus Corporation, Custom Ultrasonics, Inc., ENDOMED, and SonoScape and others are some of the prominent players at the forefront of competition in the global duodenoscopes market and are profiled in MRFR Analysis.The market of duodenoscopes is growing moderately.In addition, increasing research and development and technological advancements to identify the causes and risk factors for transmission of infectious agents with duodenoscopes and developing new solutions to minimize patient exposure is another major driver, fuelling the global duodenoscopes market growth.
UGC
Gastrointestinal (GI) infections are common problems which are resolved rapidly but aggravate in certain healthcare settings.There are recorded cases of 3-6 million children dying due to gastroenteritis worldwide.Gastrointestinal agents are recommended by doctors and clinicians to alleviate problems caused in lupus, gastroesophageal reflux disease (GERD), and others.Market Research Future (MRFR) has focused on specific trends and GI diseases in the Americas gastrointestinal drugs market report while keeping a finger on drug developments by large pharmaceutical companies.Market OutlookThe Americas Gastrointestinal Drugs Market is poised to reach a stellar size of USD 53.9 Bn by 2023.The market is anticipated to gain high dividends from over-the-counter (OTC) drugs as well as high incidence of GI diseases.Ulcertaive disease is sub-segmented into acute severe ulcerative colitis, left sided colitis, pancolitis, ulcerative proctitis, and proctosigmoiditis.By route of administration, it is segmented into parenteral, rectal, and oral.By drug category, it is segmented into anti-emetic, anti-inflammatory, acid neutralizers, laxatives & anti-diarrheal, and others.
UGC
Latest released the research study by Market Research Future (MRFR) on Whipple Disease Market Revenue, offers a detailed overview of the factors influencing the global business scope.Market Research Future adds new report of “Whipple’s Disease Market Research Report – Global Forecast till 2023” it contains Company information, geographical data and Table of ContentCompetitive Analysis:Some of the key players in this market:AbbVie Inc. (US)Allergan (Republic of Ireland)Bayer AG (Germany)Bristol-Myers Squibb Company (US)Hoffmann-La Roche Ltd. (Switzerland)Henry Schein Inc. (US),Pfizer Inc. (US)Also Read - https://www.medgadget.com/2020/09/analytics-study-during-covid-19-for-healthcare-analytics-market-claims-towering-shares-in-future-global-healthcare-analytics-industry.htmlMarket Segments:The global Whipple’s disease market is segmentedOn the basis of Diagnosis, which includes physical exam, biopsy, blood tests, polymerase chain reaction, endoscopy, and others.Biopsy plays important role in diagnosis of this disorder, these tests include needle biopsy, CT-guided biopsy, ultrasound-guided biopsy, aspiration biopsy (fine-needle aspiration), skin biopsy, surgical biopsy, and others.Supplements include vitamin supplements, mineral supplementsOn the basis of End User, it is segmented into hospitals & clinics, academic institutes, medical research centersMarket Highlight:Whipple’s disease (WD) is a rare, chronic, systemic infectious bacterial disease caused by Tropheryma whipplei that affects gastrointestinal system, especially,  the small intestine.Some common symptoms of this disease are weight loss, diarrhea, abdominal cramping and pain, weakness, fatigue, anemia, inflamed joints, and some other less common symptoms.The prevalence is one in one million people.The prevalence of this diseases is more in men than women.Ongoing research and clinical trial to find effective cure drive the growth of market.
6
UGC
Market Research Future, compiled report on  Endoscopy Device Market delivers a holistic view on market valuations, market size, profit estimations, SWOT analysis and regional landscape of the market.The Endoscopy Device Market is witnessing a constant rise in revenues.Moreover, rising product launches that are FDA approved and meet the Federal Communications Commission requirements escalate market growth to furthered height.According to Market Research Future (MRFR), the global endoscopy device market is poised to reach USD 42,342.4 MN by 2023, registering 6.3% CAGR during the review period (2017 – 2023).Growing prevalence of myriads of chronic diseases, such as gastrointestinal disorders, obstetrics/gynecology diseases, and cancer, drives the endoscopy equipment and software market.Restraints: High cost of endoscopy devices.Side effects, such as infections and complications arised due to endoscopy devices.Lack of awareness for availability & benefits of endoscopy devices.Browse Complete Toc :https://www.marketresearchfuture.com/reports/endoscopy-devices-market-1967Global Endoscopy Device Market – SegmentsThe report is segmented into six dynamics;By Type      : Rigid Endoscopes, Flexible Endoscopes, Capsule Endoscopes, Robot-Assisted Endoscopes, Surgical Endoscopes, and other Endoscopes.By Therapy: Colonoscopy, Arthroscopy, Gastroscopy, Laparoscopy, Endoscopic Retrograde Cholangiopancreotography, Sigmoidoscopy, Cholangiopan Creotography, Ureteroscopy, Cystoscopy, and others.By Treatment & Procedure: Gynecologic & Pelvic Organ Conditions, Abdominal, Joint & Orthopedic Conditions, Lower Gastrointestinal Conditions, Lung & Airway Conditions, Urinary System Conditions, Upper Gastrointestinal Conditions, and others.By Application     : Gastrointestinal Endoscopy, Arthroscopy, Obstetrics/Gynecology Endoscopy, Urology Endoscopy, Bronchoscopy, Mediastinoscopy, Otoscopy, and others.By End-User          : Critical Care, Gastroenterologists, General & Pediatric Surgeons, Obstetricians-Gynecologists (ob/gyns), Orthopedic Surgeons, and others.By Regions             : Europe, Americas, Asia-Pacific, and Rest-of-the-World.Global Endoscopy Device Market – Regional AnalysisNorth America leads the global endoscopy device market.
UGC
The global ostomy care market is anticipated to reach USD 4.10 billion by 2024 according to a new study published by Polaris Market Research.Ostomy, also known as stoma is a surgical procedure that involves the removal of diseased portions of the urinary or gastrointestinal system and formation of an artificial opening in the stomach or abdomen to allow the elimination of body wastes.In Urostomy, the urine passes straight into a stoma bag and thus bypasses through urethra.Moreover, rising number of patient awareness programs on the use of ostomy products, and new product innovation are some of the key factors responsible for the growth of the market over the forecast period.However, difficult reimbursement climate and increased cost of surgical care are factors expected to stifle the growth of the global ostomy care market through the foreseeable future.The overall market is segmented on the basis of product type, end user, and region.The accessories segment of global ostomy care market is further segmented into creams, deodorants, powders & pastes, cleansers, belt, tapes, and others.On the basis of end user, the global ostomy care market is further segmented into hospitals, specialty clinics, home care settings, and ambulatory surgical centers.
UGC
Macrolide Antibiotics Market Information: By Drugs (Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin and Telithromycin), By Route of Administration (Oral, Parenteral), By Indication (Infection Due to Mycoplasma Pneumoniae, Legionella Sp, or Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis in Patients with AIDS, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, others), By End User (Hospitals, Dermatology Clinics, Pharmaceutical Companies, others) – Global Forecast till 2023Macrolide antibiotics consists of deoxy sugars attached to a macrocyclic lactone ring and are members of the polyketide class of antibiotics.The global macrolide antibiotics market is expected to surge owing to the growing prescription and the growing exposure to pathogens.The expanding healthcare sector and the growing per capita income are other drivers of the market growth.According to Market Research Future (MRFR), the global macrolide antibiotics market is expected to register a CAGR of over 12.5 % over the assessment period (2017-2023).According to the Centers for Disease Control and Prevention 2017 report, macrolides antibiotic was the second largest prescribed class of antibiotics, resulting in 44.4 million prescriptions while the prescriptions per 1,000 persons rate was 137.The prescription data also reveals that more than 24.5% prescriptions are dispensed from October to March compared to April to September.Additional factors that are fostering the market demand include the growing prevalence of skin infections and the expanding healthcare sector especially in the developing world.However, concerns over the adverse effects of macrolide antibiotics such as the gastrointestinal disturbances and adverse hepatic metabolism.Macrolide antibiotics are also reported to worsen cardiac functioning resulting in tachyarrhythmias, and even death in patients, which is hampering the market growth.Global Macrolide Antibiotics Market – SegmentsThe report is segmented into five dynamics to widen the scope of understanding,By Drugs : Azithromycin, Clarithromycin, Erythromycin, Fidaxomicin, And Telithromycin among others.By Route of Administration : Oral and Parenteral, among others.By Indication : Mycoplasma Pneumoniae, Legionella Sp, Bordetella Pertussis, Symptomatic Cat-Scratch Disease, Bacillary Angiomatosis, Peliosis Hepatis In Patients With Aids, Cerebral Toxoplasmosis, Uncomplicated Skin Infections, And Others.
UGC
  Global Digestive Enzymes Market was valued at USD xx million in 2018 and is expected to reach at USD xx million by 2026 at a CAGR of xx% over forecast period 2019-2026.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.Factors, such as the rising geriatric population, the rising prevalence of gastrointestinal disorders, increasing awareness about health, and focus on preventive health management are contributing to the global digestive enzymes market growth.However, the general public’s perception of probiotic and prebiotic products as alternatives to digestive enzymes and stringent regulatory policies affecting the growth of the market.The animal origin sub-segment holds the highest market share at a CAGR of xx% in 2018 and is expected to follow the same trend over the forecast period.The microbial enzyme, on the other hand, is expected to witness the fastest growth rate over the forecast period thanks to their low production cost and high enzymatic activity.By geography, market is segmented into North America, APAC, Europe, Latin America and MEA& Africa.The increasing prevalence of chronic gastrointestinal diseases, rapidly aging population, growing demand for preventive medicine, and the presence of major market players are primary factors contributing to the growth of market in this region.The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology.
UGC
Enteral Feeding Devices Market Overview As per Market Research Future (MRFR) analysis, the global enteral feeding devices market held a valuation of USD 2,302.4 million in 2017.Enteral feeding is a nutritional therapy process where nutrients are supplied directly to the gastrointestinal tract (GIT).Enteral feeding devices help deliver medications and nutrients directly to the stomach, duodenum, or jejunum via either the nose, mouth or direct percutaneous route.On the other hand, complications associated with enteral feeding devices, including inadvertent dislodgement of tubes and strict refund policies, are expected to hinder market growth over the forecast period.The nasoenteric feeding tubes segment is further categorized into nasogastric feeding tubes, nasojejunal feeding tubes, and nasoduodenal feeding tubes.Enteral Feeding Devices Market Regional Analysis Region-wise, the global enteral feeding devices market has been segmented into the Americas, Europe, Asia Pacific, and the Middle East & Africa.
UGC
The Serotonin Syndrome Market report presents significant details concerning market size, market share, and profit estimations to offer a panoramic view of the global market space.Moreover, this report enunciates on an accurate competitive analysis emphasizing growth strategies devised by key players in the.According to the Market Research Future (MRFR) analysis, the for Serotonin Syndrome Market is expected to hit $400 million, with CAGR estimated to rise by 2.3% from 2017-2023 (forecast period).due to the use of serotonergic drugs.Serotonin syndrome is usually caused by a synergistic effect of two or more serotonergic drugs, commonly including serotonin norepinephrine reuptake inhibitor (SNRI), selective serotonin reuptake inhibitor (SSRI), monoamine oxidase inhibitor (MAOI), tricyclic antidepressants (TCAs), amphetamines, etc.For severe cases with life-threatening gastrointestinal decontamination, using activated charcoal is performed.Sedatives such as benzodiazepines are used in agitated patients.
1
UGC
Summary – A new market study, titled "Global Prescription Gastrointestinal Drugs Market Insights, Forecast to 2025" has been featured on WiseGuyReports.The prescription drugs are widely used in the treatment of gastrointestinal disorders, crohn’s disease, ulcerative colitis, irritable bowel syndrome, diverticular disease, constipation, celiac disease, short bowel syndrome, diarrhea, intestinal obstruction and digestive enzyme disorders.The global Prescription Gastrointestinal Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.The objectives of this study are to define, segment, and project the size of the Prescription Gastrointestinal Drugs market based on company, product type, end user and key regions.Also read – https://icrowdnewswire.com/2019/02/27/prescription-gastrointestinal-drugs-market-global-key-players-trends-share-industry-size-growth-opportunities-forecast-to-2024/ This report studies the global market size of Prescription Gastrointestinal Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Prescription Gastrointestinal Drugs in these regions.This research report categorizes the global Prescription Gastrointestinal Drugs market by top players/brands, region, type and end user.This report also studies the global Prescription Gastrointestinal Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.The following manufacturers are covered in this report, with sales, revenue, market share for each company:AstraZenecaAxcan PharmaceuticalsEisaiGlaxoSmithKlineMerckSalix PharmaceuticalsMarket size by ProductOralTopicalMarket size by End UserHospital PharmaciesOnline PharmaciesRetail PharmaciesMarket size by RegionNorth AmericaUnited StatesCanadaMexicoAsia-PacificChinaIndiaJapanSouth KoreaAustraliaIndonesiaSingaporeMalaysiaPhilippinesThailandVietnamEuropeGermanyFranceUKItalySpainRussiaCentral & South AmericaBrazilRest of Central & South AmericaMiddle East & AfricaGCC CountriesTurkeyEgyptSouth AfricaThe study objectives of this report are:To study and analyze the global Prescription Gastrointestinal Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.To understand the structure of Prescription Gastrointestinal Drugs market by identifying its various subsegments.To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).Focuses on the key global Prescription Gastrointestinal Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.To project the value and sales volume of Prescription Gastrointestinal Drugs submarkets, with respect to key regions.To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.In this study, the years considered to estimate the market size of Prescription Gastrointestinal Drugs are as follows:History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2025This report includes the estimation of market size for value (million US$) and volume (K Units).Both top-down and bottom-up approaches have been used to estimate and validate the market size of Prescription Gastrointestinal Drugs market, to estimate the size of various other dependent submarkets in the overall market.Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research.
UGC
Numerous individuals use capsules for various sorts of causes, some for restorative purposes and some for nutritional purposes.Whatever your motivation in eating them, there are things about them you should know.These Empty Capsules are created to veil sharpness and horrendous scent of their substance, to build bioavailability, to help dispensability in gastrointestinal liquid, to improve photosensitivity and strength of the substance and to can make up a decreasing of different specialists.
UGC
20th Oct 2020 - Global Gastrointestinal Therapeutics Market is anticipated to reach USD 65.1 billion by 2025.The market is anticipated to rise at a healthy growth rate in the years to come.Gastrointestinal disorders are medical situations associated with the digestive system that disturb the small & large intestine, colon, and rectum.The syndromes mostly comprise peptic ulcer diseases, irritable bowel syndrome and constipation, categorized by several symptoms and signs such as bloating, pain, diarrhea, vomiting, and nausea.The market is anticipated to grow at a significant CAGR of 6.6% in the upcoming period as the scope, product types and its applications are increasing across the globe.Access Gastrointestinal Therapeutics Market Report with TOC @ https://www.millioninsights.com/industry-reports/gastrointestinal-therapeutics-marketGastrointestinal Therapeutics industry may be explored by type, Route Administration, applications, Distribution Channel and geography.The market may be explored by type as Branded, (Antacids, Enzyme Replacement Therapies, Amino salicylates, Proton Pump Inhibitors, H2 Antagonists, Laxatives, Antiemetics, Biologics, Antidiarrheals, others), Generics.
More

Top